ETAP-Lab - Preclinical Efficacy CRO
Nicolas Violle is the CEO of SYNCROSOME, a preclinical efficacy CRO, since October 2023, and has served as CEO of ETAP-Lab, an independent CRO specializing in efficacy and toxicology studies in rodents, since January 2009. With a background in neuroscience, Nicolas obtained a PhD from Université Henri Poincaré, Nancy 1, and has extensive teaching experience in biostatistics and neuroscience at various universities. Additionally, Nicolas holds multiple degrees related to management, project management, and animal experimentation, contributing to expertise in the field of preclinical research and studies that enhance bench-to-bedside translation.
This person is not in any teams
ETAP-Lab - Preclinical Efficacy CRO
ETAP-Lab provides preclinical models and services in the fields of Dermatology, Stroke and Neurodegenerative Diseases. The company has strong expertise in the field of Dermatology research and offers a large portfolio of original in vivo rodent models such as chronic skin inflammation, ischemic ulceration, psoriasis, hyperkeratosis, wound healing, atopic dermatitis, actinic keratosis, skin cancer… ETAP-Lab is also leader in the field of preclinical stroke research with a unique model portfolio consisting of innovative and translational models proposed under the brand Strok@lliance. With more than 2 decades of experience, ETAP-Lab has become a best-in-class service provider for top tier Pharma, Medical device and Agri-food companies and obtained ISO9001:v2015 certification for all its preclinical services. ETAP-Lab is listening to the needs of their clients to offer the most suited solution for products evaluation. Thus, its team is able to develop and customize relevant animal models with high translational value that fit to specific goals, from the proof-of-concept to the early development. Feel free to contact us!